novel, peripherallyacting treatments with improved safety profiles. Ember’s unique approach leverages recent research breakthroughs in brown fat biology to develop a pipeline of proprietary large and small molecules designed to amplify the body’s innate ability to efficiently burn fuels like glucose.

Ember’s expertise is also driving the development of the next generation of highly selective insulin sensitizers that have robust anti-diabetic effects, but lack the serious side effects of

currently approved insulin sensitizers. Formerly known as Adipothermics, Ember Therapeutics is a private company launched in 2011 by renowned scientific founders, an experienced leadership team and Third Rock Ventures.